Healios K.K. (TYO:4593)
Japan · Delayed Price · Currency is JPY 333.00
-6.00 (-1.77%)
May 12, 2026, 3:30 PM JST
Healios K.K. Revenue
In the year 2025, Healios K.K. had annual revenue of 104.00M JPY, down -81.43%. Healios K.K. had revenue of 25.00M in the quarter ending December 31, 2025, with 38.89% growth.
Revenue
104.00M
Revenue Growth
-81.43%
P/S Ratio
432.27
Revenue / Employee
1.39M
Employees
75
Market Cap
44.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 104.00M | -456.00M | -81.43% |
| Dec 31, 2024 | 560.00M | 439.00M | 362.81% |
| Dec 31, 2023 | 121.00M | 31.00M | 34.44% |
| Dec 31, 2022 | 90.00M | 49.00M | 119.51% |
| Dec 31, 2021 | 41.00M | 14.00M | 51.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takara Bio | 44.15B |
| Nxera Pharma | 34.23B |
| RaQualia Pharma | 3.98B |
| ReproCELL | 2.52B |
| Japan Tissue Engineering | 2.18B |
| Stella Pharma | 968.00M |
| AnGes | 908.00M |
| Cuorips | 356.00M |